via Monash University
- A world-first discovery by Australian researchers could become a game-changer for patients at risk of rapid health deterioration, such as heart complications, stroke, sepsis and cancer.
- Researchers developed an antibody as a biosensor, to continuously monitor rapid changes in the concentration of EGFR, a protein present on cancer cells and in body fluids.
- Traditional diagnostic tests involve sampling something tissue, blood or other bodily fluids, and taking it to a lab for further analysis. This new technique opens the door to monitor dynamic changes in real-time at the bedside.
A world-first discovery by researchers at Monash University and The University of Queensland could lead to faster and more effective treatments for chronic health complications, such as cardiovascular disease and cancer, with ‘fluorescent’ in vivo biosensors.
The research team, led by Dr Simon Corrie from Monash University’s Department of Chemical Engineering and the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, took an antibody that binds EGFR (epidermal growth factor receptor) proteins and engineered it to monitor the concentration of EGFR proteins in serum solutions over time.
Co-authors of the paper, published in ACS Sensors, are Dr Christian Fercher, Dr Martina Jones and Professor Stephen Mahler from The University of Queensland and the Australian Institute for Bioengineering and Nanotechnology.
An inability to detect the growth of EGFR proteins in humans can be associated with the development of a number of tumours, including cancer, as well as the onset of diseases like Alzheimer’s.
Using an independent detection mechanism developed by the research team, involving fluorescent dyes, researchers created a biosensor from a well-known antibody that was able to ‘read out’ changes of the EGFR protein in real-time by monitoring detectable changes in the fluorescence spectra.
The ability to monitor protein biomarker concentrations in body fluids in real-time is invaluable for tracking patients at risk of rapid deterioration, including those requiring personalised drug monitoring or those at high risk of complications arising from critical conditions, like sepsis, heart attack or tumour response to treatment.
No one has been able to engineer an antibody for continuous testing until now.
“All the diagnostic tests that we are familiar with involve sampling something (blood, urine, tissue) at a particular point in time and taking the same to a lab to interrogate it. But for patients suffering from acute conditions, in which time to diagnose and rapid treatment are very important, this traditional diagnostic process is not good enough,” Dr Corrie said.
“Monitoring dynamic changes in proteins, for example protein levels increasing or decreasing over time, is likely to provide much more detailed information about a disease or treatment process, but the sensors required to do this don’t exist outside of continuous glucose testing for diabetes.
“Our capacity to create antibodies, which bind reversibly to targets and can be ‘read out’ using fluorescence, means we can develop in vivo sensors. These sensors can monitor the levels of critical biomarkers as they change over time in response to a disease or treatment, rather than just sending a sample to a lab and getting a snapshot in a day or two.
“These biomarkers could include the amount of surface proteins on a cancer cell and whether or not a drug causes them to reduce in size, therefore testing the efficacy of treatment. It can also be used to monitor the concentration of potentially toxic drugs, like some antibiotics.”
This discovery was able to engineer an antibody fragment capable of reversibly binding to a protein analyte (scFv) in a chemical solution, while retaining the specificity of the original antibody sequence.
Through their efforts, continuous in vitro monitoring over multiple hours was successfully recorded.
“Work is underway to employ dyes that are much better suited to medical applications,” Dr Corrie said.
“In future, we expect that this process will be used to generate a range of biosensors that can monitor protein concentration continuously inside the human body, through a biopharmaceutical process, or in the environment.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Fluorescent in vivo biosensors
- Nanotechnology and the fight against COVID-19on June 29, 2021 at 5:34 am
Involving computational detection allows greater sensitivity than can be seen by the human eye, and similar detection systems have been developed with fluorescent particles that bind with the ...
- Face masks that can diagnose COVID-19on June 28, 2021 at 10:09 am
They created biosensors that can detect pathogen-derived RNA molecules and coupled them with a colored or fluorescent indicator protein, then embedded the genetic circuit into paper to create a ...
- How Chip Technology Can Help Diagnostics Manufacturerson June 27, 2021 at 5:00 pm
For example, with the use of photonic waveguides, Imec has built a fluorescent immunoassay which could be used ... A similar story as for photonics-based biosensors can be told for ion sensing and ...
- Mouse redox histology using genetically encoded probeson June 6, 2021 at 5:00 pm
For mice, direct in vivo imaging with fluorescent biosensors is limited to superficial tissues or to those tissues that can be accessed by surgical intervention (8). Thus, redox imaging methods are ...
- How can nanomaterials help in the fight against COVID-19?on June 3, 2021 at 9:38 am
However, these materials can interact with DNA in animals, so their use in vivo is still questionable ... of these nanoparticles have been used in biosensors for virus and other pathogen detection.
Go deeper with Google Headlines on:
Fluorescent in vivo biosensors
Go deeper with Bing News on:
- Lux Research Predicts a $25 Billion Market for Wearable Biosensors by 2030on June 24, 2021 at 4:52 am
In contrast, wearable electronics offer biosensing capabilities that are convenient and allow consumers to monitor their health on a continuous basis and derive insights. "Patients today face ...
- Lux Research Predicts a $25 Billion Market for Wearable Biosensors by 2030on June 24, 2021 at 4:34 am
Biosensors offer tremendous promise as convenient, easy-to-use, and low-cost solutions to monitor underlying physiological conditions compared to other incumbent diagnostic techniques. This will lead ...
- Integrated Device Design Critical to Rapid Medical IoT Developmenton June 13, 2021 at 5:00 pm
functionalization have enabled new strides in optical biosensing. As explained later ... Above: Excelitas’ new CaliPile TPiS 1S 1385 compact thermopile sensor enables continuous monitoring ...
- Jalean L. Heikenfeld (Studer)on June 8, 2021 at 5:00 pm
Looking for something else? Search below to find a doctor with that skillset. Membrane isolation of repeated-use sweat stimulants for mitigating both direct dermal contact and sweat dilution.
- Wireless smart contact lens for diabetic diagnosis and therapyon June 6, 2021 at 5:00 pm
Here, we developed smart contact lenses for both continuous glucose monitoring and treatment of ... flexible electrical circuits and a microcontroller chip for real-time electrochemical biosensing, on ...